Race Treatment and Cardiovascular Health: A Study of Men with Prostate Cancer
Annual rept. 21 Sep 2010-20 Sep 2011
HENRY FORD HEALTH SYSTEM DETROIT MI
Pagination or Media Count:
As more men live with their prostate cancer, they face increased risk of cardiovascular disease CVD. This risk is intensified by treatment type, in particular androgen deprivation therapy ADT. There is a paucity of data exploring the risk of CVD among minority men with prostate cancer overall or by treatment type. The purpose of this study is to examine race-specific CVD risk in men with prostate cancer, overall and by treatment type. A total of 2,000 prostate cancer cases 1,000 each African American and Caucasian have been identified and over 1,200 have been abstracted. Overall, approximately 75 of men had a post-diagnosis lipid profile drawn. However, lipid monitoring was lacking among those who were ever given ADT, predominantly in the Caucasian group, demonstrating a potential gap in CVD risk factor monitoring in a high-risk group. In our population, ADT increased cholesterol levels in both African-American and Caucasian men with prostate cancer, which suggests a need for guidelines for regular screening of men treated with ADT. We are now exploring the role of pre- and post-diagnosis of hypercholesterolemia, use of cholesterol-lowering medications, and the role of additional cardiovascular risk factors e.g., hypertension, diabetes on risk of events in this population of African-American and Caucasian prostate cancer cases.
- Sociology and Law
- Medicine and Medical Research